Marc Beer is the CEO and the co-founder of Renovia incorporated, which is a new start-up. They are positioned to move along full steam ahead with their new products that focus on pelvic floor disorders. The company was successful in a series b round of funding in the amount of $32 million dollars. In addition to that, it was able to score $10 million dollars more in new venture debt capital.
The company is located in Boston and continues to develop and create therapeutic and diagnostic products. They are all geared toward treating pelvic floor disorders such as urinary incontinence. Studies have shown that the research reveals nearly 250 million women are affected by this issue. The FDA approved Renovia is its initial product called Leiva back in April. One of the funders that joined the series b funding round was The Longwood fund, a well known investment firm, that targets healthcare focused companies such as Renovia. The entire process was guided by a New York company called Ascension ventures out of Missouri and Perceptive Advisors. All funding is raised for the testing and development of adding four diagnostic and therapeutic products. This also includes a new Leva device which is an addition.
Beer states that they are extremely thrilled to get the support of these groups who lead in the industry of healthcare as investors who share their same vision. He further goes on to say that they also understand his company is always looking for ways to better diagnose, improve and treat women living with pelvic disorders. In the rest of his statement. Beers shared that Renovia is actively combining proprietary and new sensor technologies that will form with a digital health platform. The goal is to give customers information that is valuable and up to date about new treatments. Beer also states that his company has a firm understanding when it comes to pelvic floor disorders and hopes to help people become more knowledgeable about it.
Marc Beer has nearly two and a half decades of experience when it comes to the commercialization and development in biotechnology, diagnostics, pharmaceuticals, and devices. His company continues its mission when it comes to fighting new therapies for patients suffering from these rare debilitating diseases. It was in 2010, When Beer’s company marketed a product with the title of Juxtapid and received media approval from the U.S. Food and Drug Administration. During the time this drug was on the market it was approved in nearly 36 countries across the world. Learn more : https://www.slideshare.net/MarcBeer